Cocktail treatment with EGFR-specific and CD133-specific chimeric anti
- This topic has 0 replies, 1 voice, and was last updated 7 years, 7 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.
“This case suggests that CART cocktail immunotherapy may be feasible for the treatment of CCA as well as other solid malignancies; however, the toxicities, especially the epidermal/endothelial damages, require a further investigation.”
https://www.ncbi.nlm.nih.gov/pubmed/28057014
Viewing 1 post (of 1 total)
- The forum ‘New Developments’ is closed to new topics and replies.